Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Mitchell G. Miglis; Charles H. Adler; Elena Antelmi; Dario Arnaldi; Luca Baldelli; Bradley F. Boeve; Matteo Cesari; Irene Dall'Antonia; Nico J. Diederich; Kathrin Doppler; Petr Dušek; Raffaele Ferri; Jean François Gagnon; Ziv Gan-Or; Wiebke Hermann; Birgit Högl; Michele T. Hu; Alex Iranzo; Annette Janzen; Anastasia Kuzkina; Jee Young Lee; Klaus L. Leenders; Simon J.G. Lewis; Claudio Liguori; Jun Liu; Christine Lo; Kaylena A. Ehgoetz Martens; Jiri Nepozitek; Giuseppe Plazzi; Federica Provini; Monica Puligheddu; Michal Rolinski; Jan Rusz; Ambra Stefani; Rebekah L.S. Summers; Dallah Yoo; Jennifer Zitser; Wolfgang H. Oertel

doi:10.1016/S1474-4422(21)00176-9

Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Mitchell G. Miglis, Charles H. Adler, Elena Antelmi, Dario Arnaldi, Luca Baldelli, Bradley F. Boeve, Matteo Cesari, Irene Dall'Antonia, Nico J. Diederich, Kathrin Doppler, Petr Dušek, Raffaele Ferri, Jean François Gagnon, Ziv Gan-Or, Wiebke Hermann, Birgit Högl, Michele T. Hu, Alex Iranzo, Annette Janzen, Anastasia KuzkinaJee Young Lee, Klaus L. Leenders, Simon J.G. Lewis, Claudio Liguori, Jun Liu, Christine Lo, Kaylena A. Ehgoetz Martens, Jiri Nepozitek, Giuseppe Plazzi, Federica Provini, Monica Puligheddu, Michal Rolinski, Jan Rusz, Ambra Stefani, Rebekah L.S. Summers, Dallah Yoo, Jennifer Zitser, Wolfgang H. Oertel

Research output: Contribution to journal › Review article › peer-review

Abstract

Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop.

Original language	English (US)
Pages (from-to)	671-684
Number of pages	14
Journal	The Lancet Neurology
Volume	20
Issue number	8
DOIs	https://doi.org/10.1016/S1474-4422(21)00176-9
State	Published - Aug 2021

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1016/S1474-4422(21)00176-9

Cite this

Miglis, M. G., Adler, C. H., Antelmi, E., Arnaldi, D., Baldelli, L., Boeve, B. F., Cesari, M., Dall'Antonia, I., Diederich, N. J., Doppler, K., Dušek, P., Ferri, R., Gagnon, J. F., Gan-Or, Z., Hermann, W., Högl, B., Hu, M. T., Iranzo, A., Janzen, A., ... Oertel, W. H. (2021). Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. The Lancet Neurology, 20(8), 671-684. https://doi.org/10.1016/S1474-4422(21)00176-9

Miglis, MG, Adler, CH, Antelmi, E, Arnaldi, D, Baldelli, L, Boeve, BF, Cesari, M, Dall'Antonia, I, Diederich, NJ, Doppler, K, Dušek, P, Ferri, R, Gagnon, JF, Gan-Or, Z, Hermann, W, Högl, B, Hu, MT, Iranzo, A, Janzen, A, Kuzkina, A, Lee, JY, Leenders, KL, Lewis, SJG, Liguori, C, Liu, J, Lo, C, Ehgoetz Martens, KA, Nepozitek, J, Plazzi, G, Provini, F, Puligheddu, M, Rolinski, M, Rusz, J, Stefani, A, Summers, RLS, Yoo, D, Zitser, J & Oertel, WH 2021, 'Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder', The Lancet Neurology, vol. 20, no. 8, pp. 671-684. https://doi.org/10.1016/S1474-4422(21)00176-9

@article{39615d6cf64942658fc7ae0d0968ca5e,

title = "Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder",

abstract = "Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop.",

author = "Miglis, {Mitchell G.} and Adler, {Charles H.} and Elena Antelmi and Dario Arnaldi and Luca Baldelli and Boeve, {Bradley F.} and Matteo Cesari and Irene Dall'Antonia and Diederich, {Nico J.} and Kathrin Doppler and Petr Du{\v s}ek and Raffaele Ferri and Gagnon, {Jean Fran{\c c}ois} and Ziv Gan-Or and Wiebke Hermann and Birgit H{\"o}gl and Hu, {Michele T.} and Alex Iranzo and Annette Janzen and Anastasia Kuzkina and Lee, {Jee Young} and Leenders, {Klaus L.} and Lewis, {Simon J.G.} and Claudio Liguori and Jun Liu and Christine Lo and {Ehgoetz Martens}, {Kaylena A.} and Jiri Nepozitek and Giuseppe Plazzi and Federica Provini and Monica Puligheddu and Michal Rolinski and Jan Rusz and Ambra Stefani and Summers, {Rebekah L.S.} and Dallah Yoo and Jennifer Zitser and Oertel, {Wolfgang H.}",

note = "Funding Information: BFB was supported by grants (R34 AG056639, P30 AG62677, U01 NS100620) from the US NIH. JR (NU20-08-00445) and PD (NU20-08-00445) were supported by grants from the Czech Health Research Council. WHO was supported by ParkinsonFonds Deutschland. No funding source had any role in the writing of the manuscript or the decision to submit for publication. No authors have been paid to write this Review by a pharmaceutical company or other agency. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2021",

month = aug,

doi = "10.1016/S1474-4422(21)00176-9",

language = "English (US)",

volume = "20",

pages = "671--684",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Lancet Publishing Group",

number = "8",

}

TY - JOUR

T1 - Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

AU - Miglis, Mitchell G.

AU - Adler, Charles H.

AU - Antelmi, Elena

AU - Arnaldi, Dario

AU - Baldelli, Luca

AU - Boeve, Bradley F.

AU - Cesari, Matteo

AU - Dall'Antonia, Irene

AU - Diederich, Nico J.

AU - Doppler, Kathrin

AU - Dušek, Petr

AU - Ferri, Raffaele

AU - Gagnon, Jean François

AU - Gan-Or, Ziv

AU - Hermann, Wiebke

AU - Högl, Birgit

AU - Hu, Michele T.

AU - Iranzo, Alex

AU - Janzen, Annette

AU - Kuzkina, Anastasia

AU - Lee, Jee Young

AU - Leenders, Klaus L.

AU - Lewis, Simon J.G.

AU - Liguori, Claudio

AU - Liu, Jun

AU - Lo, Christine

AU - Ehgoetz Martens, Kaylena A.

AU - Nepozitek, Jiri

AU - Plazzi, Giuseppe

AU - Provini, Federica

AU - Puligheddu, Monica

AU - Rolinski, Michal

AU - Rusz, Jan

AU - Stefani, Ambra

AU - Summers, Rebekah L.S.

AU - Yoo, Dallah

AU - Zitser, Jennifer

AU - Oertel, Wolfgang H.

N1 - Funding Information: BFB was supported by grants (R34 AG056639, P30 AG62677, U01 NS100620) from the US NIH. JR (NU20-08-00445) and PD (NU20-08-00445) were supported by grants from the Czech Health Research Council. WHO was supported by ParkinsonFonds Deutschland. No funding source had any role in the writing of the manuscript or the decision to submit for publication. No authors have been paid to write this Review by a pharmaceutical company or other agency. Publisher Copyright: © 2021 Elsevier Ltd

PY - 2021/8

Y1 - 2021/8

N2 - Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop.

AB - Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop.

UR - http://www.scopus.com/inward/record.url?scp=85110583357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85110583357&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(21)00176-9

DO - 10.1016/S1474-4422(21)00176-9

M3 - Review article

C2 - 34302789

AN - SCOPUS:85110583357

SN - 1474-4422

VL - 20

SP - 671

EP - 684

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 8

ER -

Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this